Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | MGAM | O43451 | 4/20 | 0.48 |
| ▸ | SI | P14410 | 4/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2621332 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL10032055 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL14747294 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL1296044 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL22251726 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL24872329 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL10236872 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL14856334 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL7098842 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI | |
| SCHEMBL12352431 | 1.00 | LGALS8 (0.56) | LGALS8L3MBTL1MAPTMGAMSI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023147161-A2 | NICOTINATE AND NICOTINAMIDE RIBOSIDE-BASED COMPOUNDS AND DERIVATIVES THEREOF | New Frontier Bio, Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-7579343-B2 | Pyrrolo-thiazines and processes for the preparation and use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070055062-A1 | Pyrrolo-thiazines and processes for the preparation and use thereof | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070055062-A1 | Pyrrolo-thiazines and processes for the preparation and use thereof | TALDO1, THPO, PPOX | LGALS8 3295/4885L3MBTL1 4446/4885MAPT 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.